Deonni Stolldorf, Ph.D.
- Associate Professor of Nursing
Deonni Stolldorf, Ph.D.
- Associate Professor of Nursing
615-343-0637
deonni.stolldorf@vanderbilt.edu
Research Program
This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.
Danxia Yu, Ph.D.
- Associate Professor of Medicine (Epidemiology)
Danxia Yu, Ph.D.
- Associate Professor of Medicine (Epidemiology)
615-936-7389
danxia.yu@vumc.org
Research Program
Research Description
Christine Smith, M.D.
- Assistant Professor
Christine Smith, M.D.
- Assistant Professor
christine.m.smith.2@vumc.org
Research Program
Research Description
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Eben Rosenthal, M.D.
- Professor and Chair, Department of Otolaryngology–Head and Neck Surgery
- Co-Leader, Translational Research and Interventional Oncology Research Program
- Guy M. Maness Professor of Otolaryngology
- Barry and Amy Baker Chair in Laryngeal, Head and Neck Research
- Professor, Department of Pathology, Microbiology and Immunology
Eben Rosenthal, M.D.
- Professor and Chair, Department of Otolaryngology–Head and Neck Surgery
- Co-Leader, Translational Research and Interventional Oncology Research Program
- Guy M. Maness Professor of Otolaryngology
- Barry and Amy Baker Chair in Laryngeal, Head and Neck Research
- Professor, Department of Pathology, Microbiology and Immunology
e.rosenthal@vumc.org
Research Program
Research Description
Courtney Penn, M.D.
- Assistant Professor of Obstetrics and Gynecology
Courtney Penn, M.D.
- Assistant Professor of Obstetrics and Gynecology
courtney.penn@vumc.org
Research Program
Research Description
Juan Arroyo Ornelas, M.D., Ph.D.
- Assistant Professor of Medicine (Nephrology and Hypertension), Cell & Developmental Biology, and Molecular Physiology & Biophysics
Juan Arroyo Ornelas, M.D., Ph.D.
- Assistant Professor of Medicine (Nephrology and Hypertension), Cell & Developmental Biology, and Molecular Physiology & Biophysics
juan.p.arroyo@vumc.org
Research Program
Research Description
ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response.
ABNL MARRO 001 (AM-001) is an Open label, phase 1/2 study within the framework of the ABNL-MARRO that will test novel treatment combinations in MDS/MPN. Each Arm of AM-001 will test an active myeloid target compound in combination with ASTX727, an oral drug combining fixed doses of the DNA methyltransferase inhibitor (DNMTi) decitabine and the cytidine deaminase inhibitor E7727, also known as cedazuridine in a single tablet.
